New data from the European Hematology Association 2026 congress provides compelling evidence for triple-drug combination therapy in chronic lymphocytic leukemia. The key finding: patients receiving pirtobrutinib added to venetoclax-rituximab demonstrate substantially improved progression-free survival compared to those receiving the standard dual combination alone.
This statistically significant benefit addresses a critical clinical gap for patients with relapsed or refractory disease who have become resistant to prior BTK inhibitors. The non-covalent mechanism of pirtobrutinib offers a distinct pharmacological advantage, overcoming resistance patterns observed with conventional covalent BTK inhibitors. For oncologists treating heavily pretreated CLL patients, these results provide evidence-based rationale for the triple-therapy approach as a viable next-line option.
Read the full article on GMJ Newsroom.
Was this article helpful?
